Sign In
Buy PIRS
$13.60
+0 (+0%)
At Close: Mar 12, 2025
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q4 2020 Results - Earnings Call Transcript
12:33pm, Tuesday, 30'th Mar 2021
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q4 2020 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Misses Revenue Estimates
10:37am, Tuesday, 30'th Mar 2021
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -8.33% and -50.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st
Pieris Pharmaceuticals: Q4 Earnings Insights
07:18am, Tuesday, 30'th Mar 2021
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 5.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 333.33% over the past year to ($0.2
Pieris Pharmaceuticals Reports Full-Year 2020 Financial Results and Provides Corporate Update
07:00am, Tuesday, 30'th Mar 2021
Company To Host an Investor Conference Call on Tuesday, March 30, 2021 at 8:00 AM EDT Pieris achieves $13 million milestone from AstraZeneca for initiation of PRS-060/AZD1402 phase 2a study and AstraZ
Pieris Pharmaceuticals's Earnings Outlook
10:05am, Monday, 29'th Mar 2021
On Tuesday, March 30, Pieris Pharmaceuticals (NASDAQ:PIRS) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
PIRS Stock Price Increases Over 10% Pre-Market: Why It Happened
08:32am, Thursday, 25'th Mar 2021
The stock price of Pieris Pharmaceuticals Inc (NASDAQ: PIRS) increased by over 10% pre-market. This is why it happened.
Pieris Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen, a Clinical Trial and Supply Agreement to Evaluate Cinrebafusp Alfa (PRS-343) in Combination with TUKYSA(R) (tucatinib) in Gastric Cancer, and Strategic Equity Investment by Seagen
08:00am, Thursday, 25'th Mar 2021
Seagen will supply Pieris with TUKYSA® to evaluate the drug in combination with cinrebafusp alfa (PRS-343) in gastric cancer Pieris' co-development option for one program from existing multi-target c
Analysts Estimate Pieris Pharmaceuticals (PIRS) to Report a Decline in Earnings: What to Look Out for
01:41pm, Friday, 05'th Mar 2021
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Lifts Partial Clinical Hold on PRS-343 Phase 1 Studies
08:00am, Tuesday, 19'th Jan 2021
BOSTON, MA / ACCESSWIRE / January 19, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® te
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q3 2020 Results - Earnings Call Transcript
12:05pm, Wednesday, 04'th Nov 2020
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q3 2020 Results - Earnings Call Transcript
Pieris Pharmaceuticals: Q3 Earnings Insights
07:58am, Wednesday, 04'th Nov 2020
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q3 results.
